glp 1 gip GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) Potential Use of GLP-1 and

GLP-1 (glucagon-like peptide-1) analogues have emerged as game-changers in the management of type 2 diabetes and obesity, thanks to their dual role in glucose regulation and weight reduction

Whats next in the pipeline

Depending on the medication and the patient population, research and approvals have supported benefits in areas like: Cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity (for specific products) Kidney protection in people with type 2 diabetes and chronic kidney disease (semaglutide showed benefit in a large kidney outcomes trial) Obstructive sleep apnea in adults with obesity (tirzepatide has an FDA-approved indication for moderate to severe OSA in this population) Fatty liver disease and MASH (semaglutide has shown promising results in phase 3 research) Addiction to opioids and alcohol This is why these medications are now part of bigger medical conversations: heart, kidney, liver, sleep health and substance abuse

GLP-1 patches do not actually contain semaglutide or tirzepatide or any other of the active ingredients found in GLP-1 medications, nor are they FDA approved or proven to be effective

Some major Medicare Advantage insurers have begun using a prior authorization process to make sure that theyre only covering GLP-1 drugs for patients who have been diagnosed with type 2 diabetes

Human skin is composed of three main layers